ALK+非小细胞肺癌癌症患者与阿替尼相关的体重增加：四项前瞻性临床试验的个体患者数据汇总分析

文章预览

SCI 1 January 2025 Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials (Journal of clinical oncology, if=42.10) Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC.  Correspondence: a.dingemans@erasmusmc.nl  Purpose 目的 Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics. 体重增加是阿来替尼已知的不良事件（AE）。本研究评估了实际体重增加随时间的变化，并探讨了其与基线特征的关系。 Methods 方法 A pooled analysis of individual patient data from four clinical trials (ALEX, J-ALEX, ALUR, and ML29453) was conducted. Actual weight gain was calculated as the percent change from baseline. A linear mixed model estimated weight change over ti ………………………………